US Pharma MarketingAstellas’ five-year plan includes chasing record sales and cost cuts
Astellas Pharma is aiming to double sales for its five key medicines, including Pfizer-partnered bladder cancer drug Padcev, through fiscal year 2030 under a new five-year strategy it published Tuesday. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the…
Astellas Pharma is aiming to double sales for its five key medicines, including Pfizer-partnered bladder cancer drug Padcev, through fiscal year 2030 under a new five-year strategy it published Tuesday.
The Japanese drugmaker
Source: Endpoints News